LENZ Therapeutics (LENZ) Long-Term Investments (2022)
LENZ Therapeutics' (LENZ) quarterly Long-Term Investments came in at $15.3 million in Q4 2022, up 14.32% on a QoQ basis from $13.4 million in Q3 2022.
LENZ Therapeutics (LENZ) Long-Term Investments (2022) Analysis & Trends
LENZ Therapeutics (LENZ) has 1 years of Long-Term Investments data on file, last reported at $15.3 million in Q4 2022.
- On a quarterly basis, Long-Term Investments changed N/A year-over-year to $15.3 million in Q4 2022; TTM through Dec 2022 was $15.3 million, a N/A change from a year earlier, with the FY2022 full-year figure at $15.3 million, changed N/A from the prior year.
- Long-Term Investments for Q4 2022 stood at $15.3 million, up from $13.4 million in the prior quarter.
- Over the last five years, Long-Term Investments for LENZ reached as high as $15.3 million in Q4 2022 and fell as low as $6.0 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 505,194.89 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | LENZ Therapeutics | 158.34 Mn | 158.34 Mn | 825,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 15.32 Mn |
| Sep 30, 2022 | 13.40 Mn |
| Jun 30, 2022 | 5.99 Mn |
| Mar 31, 2022 | 12.93 Mn |